Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00694135 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis
A Phase 2 study, sponsored by Eyegate Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00694135: Completed Phase 2 study, sponsored by Eyegate Pharmaceuticals.
NCT00694135 is a Phase 2 study that has completed, run by Eyegate Pharmaceuticals. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00694135, a Phase 2 study, has completed, sponsored by Eyegate Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment uveitis.
Primary Outcome
Proportion of subjects with an anterior chamber cell (ACC) score of zero at Days 14 and 28
Interventions
- DRUG EGP-437 1.6 mA-min at 0.4 with EyeGate® II System
- DRUG EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System
- DRUG EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System
- DRUG EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
What the finished NCT00694135 record still lists
NCT00694135 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 4 interventions - of which EGP-437 1.6 mA-min at 0.4 with EyeGate® II System is the first listed.
NCT00694135 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00694135 about?
NCT00694135 is a clinical study titled "Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis". The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment uveitis.
What is the current status of trial NCT00694135?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2008-06. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00694135?
The interventions under investigation include: EGP-437 1.6 mA-min at 0.4 with EyeGate® II System (DRUG), EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System (DRUG), EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System (DRUG), EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System (DRUG).
Who is sponsoring clinical trial NCT00694135?
This trial is sponsored by Eyegate Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00694135's enrollment target sits among peer trials
40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia